Introducing the concept of virtual control groups into preclinical toxicology testing.


Journal

ALTEX
ISSN: 1868-8551
Titre abrégé: ALTEX
Pays: Germany
ID NLM: 100953980

Informations de publication

Date de publication:
2020
Historique:
received: 31 01 2020
accepted: 31 03 2020
entrez: 4 4 2020
pubmed: 4 4 2020
medline: 27 7 2021
Statut: ppublish

Résumé

Sharing legacy data from in vivo toxicity studies offers the opportunity to analyze the variability of control groups stratified for strain, age, duration of study, vehicle and other experimental conditions. Historical animal control group data may lead to a repository, which could be used to construct virtual control groups (VCGs) for toxicity studies. VCGs are an established concept in clinical trials, but the idea of replacing living beings with virtual data sets has so far not been introduced into the design of regulatory animal studies. The use of VCGs has the potential of a 25% reduction in animal use by replacing the control group animals with existing randomized data sets. Prerequisites for such an approach are the availability of large and well-structured control data sets as well as thorough statistical evaluations. the foundation of data sharing has been laid within the Innovative Medicines Initiatives projects eTOX and eTRANSAFE. For a proof of principle participating companies have started to collect control group data for subacute (4-week) GLP studies with Wistar rats (the strain preferentially used in Europe) and are characterizing these data for its variability. In a second step, the control group data will be shared among the companies and cross-company variability will be investigated. In a third step, a set of studies will be analyzed to assess whether the use of VCG data would have influenced the outcome of the study compared to the real control group.

Identifiants

pubmed: 32242633
doi: 10.14573/altex.2001311
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

343-349

Auteurs

Thomas Steger-Hartmann (T)

Bayer AG, Pharmaceuticals, Investigational Toxicology, Berlin, Germany.

Annika Kreuchwig (A)

Bayer AG, Pharmaceuticals, Investigational Toxicology, Berlin, Germany.

Lea Vaas (L)

Bayer AG, Pharmaceuticals, Investigational Toxicology, Berlin, Germany.

Jörg Wichard (J)

Bayer AG, Pharmaceuticals, Investigational Toxicology, Berlin, Germany.

Frank Bringezu (F)

Merck Healthcare KGaA, Biopharma and Non-Clinical Safety, Darmstadt, Germany.

Alexander Amberg (A)

Sanofi, Preclinical Safety, Frankfurt, Germany.

Wolfgang Muster (W)

Roche Pharmaceutical Research & Early Development, Pharmaceutical Sciences, Roche Innovation Center, Basel, Switzerland.

Francois Pognan (F)

Novartis Institute for Biomedical Research, Basel Switzerland.

Chris Barber (C)

Lhasa Ltd. Leeds, UK.

Articles similaires

Humans Recurrence Male Female Middle Aged
Humans Chondrocytes Osteoarthritis Matrix Metalloproteinase 13 Drug Discovery
Humans Self-Control Longitudinal Studies Child, Preschool Child

Classifications MeSH